Inventiva price target lowered to $35 from $36 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Inventiva to $35 from $36 and keeps a Buy rating on the shares. Modifications to lanifibranor’s pivotal program leverages the recent FDA guidance for full approval pathway, the analyst tells investors in a research note.